Kbi-092 !link!

This protein is a central mediator in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. These pathways are frequently hijacked by cancer cells to promote inflammation and evade cell death, particularly in patients who have failed prior FLT3 inhibitor therapy.

By inhibiting both FLT3 and IRAK4 simultaneously, KBI-092 aims to overcome the "bypass mechanisms" cancer cells use to survive when only one pathway is blocked. KBI-092

As of late 2025, KBI-092 has moved into the active clinical testing phase: This protein is a central mediator in the

The ongoing research into KBI-092 represents a shift toward more sophisticated, multi-targeted therapies that address the inherent complexity and adaptability of blood cancers. HPB 092 - AdisInsight KBI-092